Trovagene Inc. (NASDAQ:TROV) shares fell 3.4% during trading on Thursday . The company traded as low as $4.86 and last traded at $4.89, with a volume of 241,804 shares traded. The stock had previously closed at $5.06.

A number of brokerages recently commented on TROV. Maxim Group raised their price target on Trovagene from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Piper Jaffray Cos. set a $4.00 price target on Trovagene and gave the stock a “hold” rating in a research report on Friday, August 5th. Zacks Investment Research upgraded Trovagene from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Wednesday. Cantor Fitzgerald upgraded Trovagene from a “hold” rating to a “buy” rating and raised their price target for the stock from $5.00 to $7.00 in a research report on Monday, August 8th. Finally, Argus cut Trovagene from a “buy” rating to a “hold” rating in a research report on Thursday, April 28th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.13.

The firm’s market cap is $148.32 million. The stock’s 50-day moving average price is $5.29 and its 200-day moving average price is $4.99.

Trovagene (NASDAQ:TROV) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.03. On average, equities analysts forecast that Trovagene Inc. will post ($1.33) EPS for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.